Thrombin receptor PAR4 cross-activates the tyrosine kinase c-met in atrial cardiomyocytes

被引:1
|
作者
Mittendorff, Claudia [1 ]
Abu-Taha, Issam [1 ]
Kassler, Lena [1 ]
Hustedt, Tobias [2 ,3 ]
Wolf, Stephanie [2 ,3 ]
Bode, Johannes G. [2 ,3 ]
Kamler, Markus [4 ]
Dobrev, Dobromir [1 ,5 ,6 ,7 ,8 ]
Fender, Anke C. [1 ]
机构
[1] Univ Duisburg Essen, Inst Pharmacol, West German Heart & Vasc Ctr, Duisburg, Germany
[2] Heinrich Heine Univ, Fac Med, Dept Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany
[3] Heinrich Heine Univ, Dusseldorf Univ Hosp, Dusseldorf, Germany
[4] Univ Hosp Essen, Dept Thorac & Cardiovasc Surg, Essen, Germany
[5] Montreal Heart Inst, Dept Med, Montreal, PQ, Canada
[6] Montreal Heart Inst, Res Ctr, Montreal, PQ, Canada
[7] Univ Montreal, Montreal, PQ, Canada
[8] Baylor Coll Med, Dept Integrat Physiol, Houston, TX USA
基金
美国国家卫生研究院;
关键词
Atrial; Cardiomyocyte; C-met; NLRP3; inflammasome; Protease-activated receptor; Thrombin; EXPRESSION; TARGET; CELLS;
D O I
10.1007/s00210-024-03436-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Thrombin supports coagulation-independent inflammation via protease-activated receptors (PAR). PAR4 is specifically increased in obese human atria, correlating with NLRP3 inflammasome activation. PAR4-mediated NLRP3 inflammasome activation in atrial cardiomyocytes is not known, nor have signaling partners been identified. Thrombin transactivates the hepatocyte growth factor receptor in some cancer cells, so we examined PAR4/c-met cross-talk in atrial cardiomyocytes and its possible significance in obesity. Cardiomyocytes from right atrial appendages (RAA) of obese patients expressed more PAR1 and PAR4 compared to non-obese. In HL-1 atrial cardiomyocytes, thrombin induced caspase-1 auto-activation and IL-1 beta maturation; IL-1 beta secretion was evoked by PAR4-activating peptide (AP), but not PAR1-AP. PAR4-AP additionally increased phosphorylated CaMKII-Thr287, mTOR-Ser2481, and Akt-Ser473 while suppressing AMPK-Thr172 phosphorylation. Total kinase levels were largely unaltered. PAR4AP rapidly increased phosphorylated c-met in HL-1 cells and over time also transcriptionally upregulated c-met. The c-met inhibitor SGX-523 abrogated the effects of PAR4-AP on CaMKII/AKT/mTOR phosphorylation but did not affect PAR4-stimulated IL-1 beta production. Obese human RAA contained more IL-1 beta, phospho-c-met, and phospho-mTOR than non-obese RAA; CamKII phosphorylation was not modified. Atria from high-fat diet (HFD) versus chow-fed mice also contained more IL-1 beta, together with higher myeloperoxidase activity, Acta2 mRNA total and phosphorylated c-met; these increases were blunted in PAR4-/- HFD-fed mice. Thrombin cross-activates c-met via PAR4 in atrial cardiomyocytes. Transactivated c-met contributes partially to PAR4-mediated signaling, but NLRP3 inflammasome activation appears to be largely independent of c-met. Abundance of PAR4 and activated c-met increases with obesity, providing therapeutic targets for management of adiposity-driven AF.
引用
收藏
页码:2783 / 2796
页数:14
相关论文
共 50 条
  • [21] c-Met receptor tyrosine kinase is expressed and activated in lung carcinoma and carcinoid tumors
    Husain, AN
    Krausz, T
    Tretiakova, M
    Ma, PC
    Salgia, R
    MODERN PATHOLOGY, 2005, 18 : 312A - 312A
  • [22] Reciprocal interaction of c-Met receptor tyrosine kinase and lncRNA HOTAIR in hepatocellular carcinoma
    Topel, H.
    Comez, D.
    Yilmaz, Y.
    Atabey, S. N.
    FEBS JOURNAL, 2017, 284 : 350 - 350
  • [23] C-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells
    E. Gregory MacEwen
    Jon Kutzke
    Jennifer Carew
    Josep Pastor
    Julie A. Schmidt
    Rachel Tsan
    Douglas H. Thamm
    Robert Radinsky
    Clinical & Experimental Metastasis, 2003, 20 (5) : 421 - 430
  • [24] The receptor tyrosine kinase c-MET as a novel therapeutic target in head and neck cancer
    Seiwert, T.
    Janamanchi, V.
    Klein-Szanto, A.
    Jagadeeswaran, R.
    Martin, L.
    Lingen, M.
    Cohen, E.
    Ridge, J.
    Vokes, E.
    Salgia, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (02): : S137 - S137
  • [25] HEPATOCYTE GROWTH-FACTOR AND ITS RECEPTOR, THE TYROSINE KINASE ENCODED BY THE C-MET PROTOONCOGENE
    VIGNA, E
    NALDINI, L
    TAMAGNONE, L
    LONGATI, P
    BARDELLI, A
    MAINA, F
    PONZETTO, C
    COMOGLIO, PM
    CELLULAR AND MOLECULAR BIOLOGY, 1994, 40 (05) : 597 - 604
  • [26] Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy
    Glodde, N.
    Bald, T.
    van den Boorn-Konijnenberg, D.
    Landsberg, J.
    Gebhardt, C.
    Long, G. V.
    Kastenmueller, W.
    Smith, M. J.
    Tueting, T.
    Hoelzel, M.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (03) : E59 - E59
  • [27] The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
    Welsh, James W.
    Mahadevan, Daruka
    Ellsworth, Ron
    Cooke, Laurence
    Bearss, David
    Stea, Baldassarre
    RADIATION ONCOLOGY, 2009, 4
  • [28] The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis
    Passelli, Katiuska
    Prat-Luri, Borja
    Merlot, Margot
    Goris, Michiel
    Mazzone, Massimiliano
    Tacchini-Cottier, Fabienne
    PLOS PATHOGENS, 2022, 18 (01)
  • [29] Chemical inhibitors of c-Met receptor tyrosine kinase stimulate osteoblast differentiation and bone regeneration
    Kim, Jung-Woo
    Lee, Mi Nam
    Jeong, Byung-Chul
    Oh, Sin-Hye
    Kook, Min-Suk
    Koh, Jeong-Tae
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 806 : 10 - 17
  • [30] The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells
    James W Welsh
    Daruka Mahadevan
    Ron Ellsworth
    Laurence Cooke
    David Bearss
    Baldassarre Stea
    Radiation Oncology, 4